impact of conditioning intensity of allo-sct for aml with molecular residual disease
Published 5 years ago • 87 plays • Length 2:34Download video MP4
Download video MP3
Similar videos
-
6:59
reduced-intensity conditioning regimens in all patients undergoing allo-hsct
-
4:03
flamsa-reduced intensity vs myeloablative conditioning for r/r aml with disease at transplantation
-
1:46
optimizing conditioning regimens in patients with aml undergoing allosct
-
2:07
the clearance of driver mutations following allosct impacts myelofibrosis disease outcomes
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
0:38
optimal time for allo-hsct in aml
-
17:31
remodeling abnormalities in mitochondrial trifunctional protein deficiency
-
3:39
tumor-related immune checkpoints and the development of targeted cancer immunotherapies
-
1:35:05
pho virtual training 24.12.2020: basics of conditioning in hsct
-
2:16
the unmet needs of patients who have visual impairment as a consequence of scd
-
1:03
reduced intensity vs myeloablative conditioning regimens in patients with aml and mds
-
3:55
the value of achieving cr after allohsct in high-risk aml
-
4:36
aml haplo-hsct outcomes
-
6:28
allohct conditioning intensity in aml in complete remission with residual disease
-
1:47
individualized machine learning predictions of allosct outcomes in aml: the harmony platform
-
2:16
the impact partnership: improving regulation and turnaround of transplant clinical trials
-
3:37
the future of aml treatment
-
1:57
the benefit of allogeneic transplantation in patients with tp53-mutated aml
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
3:46
the impact of cytogenetic risk on outcomes of haploidentical transplantation in r/r aml
-
5:14
global trends in the use of stem cell transplantation for aml